Technical Platform
Chunzhu Century Autologous Stem Cell Production Technology: Technical Principles and Features
Technical Principles
Chunzhu Century Autologous Stem Cell Production Technology utilizes the physiological effects of various small-molecule compounds to simulate in vitro the microenvironments and biological factors involved in reversing somatic cells into autologous stem cells. By leveraging distinct reverse differentiation capabilities generated from different combinations of these compounds, and by controlling the intensity and direction of this reverse differentiation, the technology enables shallow, moderate, or deep reverse differentiation. This process induces varying degrees of reverse and directed differentiation in mononuclear cells derived from blood sources.
Technical Features
Chun Zhu Bai Nian autologous stem cell production technology features comprehensive monitoring and control across all production stages and processes, delivering high speed and efficiency. It is a vital new bioenergy technology in life sciences capable of large-scale industrialization.
Technical Advantages
Chun Zhu Hundred-Year Autologous Stem Cell Production Technology uses advanced molecular biology and cell growth regulation techniques to process and cultivate mononuclear cells from blood, converting them back into autologous stem cells within 6-12 days.
- (1) proprietary technology reversely directs somatic cells into over a dozen types of autologous stem cells without genetic modification or viral vectors.
- (2) Scalable production: Generate over 100 million primary autologous stem cells in a single batch from 80–15 mL of blood within 6–12 days.
Advantages of Personalized Customization
Chun Zhu Bai Nian offers customized autologous stem cell services tailored to each client's age, gender, health status, and specific wellness goals. Our experts design a personalized stem cell treatment plan just for you.
Patented autologous stem cell production technology ensures that every individual, especially adults, has the opportunity to produce and use their own autologous stem cells at any stage of life. This delivers true practical value for applications in personal health management, anti-aging research, and the in vitro production of tissues and organs.
Industrialization Advantages
Spring's Century Autologous Stem Cell Production Technology uses your own blood cells to activate the stem cell memory of over 5% of blood cells within 6-12 days, converting them into hundreds of millions of autologous stem cells. This technology offers significant advantages: abundant raw material (40-50ml of autologous blood per collection), convenient and fast sample collection, stable production, high dedifferentiation rate, high yield, high purity, and rapid production speed. With immense potential for industrial-scale manufacturing, it holds substantial application and social value in regenerative medicine, representing a true seed cell production technology.
Safety Advantages of Autologous Stem Cell Therapy
Property Security
Derived from autologous sources with low immunogenicity, offering controllable risks of rejection, transmission, and tumorigenicity.
Safe Preparation
制备安全，整体千级的GMP洁净车间，局部百级的操作空间，无微生物和其他因素的污染
Process Safety
Autologous stem cell processing under ISO9001 quality management system
Cell Safety
符合中国CFDA标准的临床级干细胞制剂的检测和放行标准
Infusion Safety
回输安全，自体干细胞不会聚集成团，无栓塞风险
Security History
Over 10,000 applications in 24 years with no reported serious adverse reactions or side effects.
Long-term tracking
春驻百年自体干细胞生产技术1998年研发至今，与干细胞保健移植术相关的继发性细菌/病毒感染率为零，传染病感染率为零，传染病交叉感染率为零，继发性肿瘤发生率为零，死亡率为零。
Autologous stem cell applications are more effective.
技术发明人林雄斌博士建立和发展了自体干细胞抗衰老保健和疾病治疗的科学理论、进行了长期和大量的自体干细胞抗衰老的动物实践研究、自体干细胞抗衰老保健的临床研究和安全性研究和自体干细胞疾病治疗的临床研究，在世界上首创了具有世界先进水准的〖春驻百年自体干细胞抗衰老保健/疾病治疗技术〗。
〖自体干细胞抗衰老保健技术〗的临床应用，实现了机体的各种机能、皮肤、外貌、精神和生物学年龄等综合方面的整体年轻化和衰老的整体逆转，使人活得长、活得健康成为现实！
〖自体干细胞疾病治疗技术〗的临床应用，已覆盖机体九大系统相关疾病，如冠心病、心肌梗死、心功能衰竭、糖尿病、系统性红斑狼疮、类风湿性关节炎、中风、老年性痴呆、肝硬化、肝功能衰竭、肾功能衰竭、卵巢早衰等数十种疾病、数千案例，疗效极佳！
The above content is for educational and research purposes only and does not constitute medical advice. Any related applications must comply with national laws, regulations, and medical standards.